RxDoctor Payments DataLook up a doctor →

Bryant Ittiara, DO

Interventional Pain Medicine · Allen Park, MINPI 1871829069

Payments from drug & device makers

$27,748in general payments, 2019–2025

Across 682 payments — averaging $40.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Spinal Simplicity, LLC$4K
  • Nevro Corp.$3K
  • Medtronic$3K
  • Vertos Medical, Inc.$2K
  • Nalu Medical, Inc.$1K
  • plus $9K from 45 others

What the payments were for

  • Travel & lodging$8,99132%
  • Food & beverage$18,75768%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,748 in reported general payments places this provider in the 80th percentile of 88 interventional pain medicine providers in Michigan.

See all interventional pain medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$125,475
Medicare patients
134
Services billed
1,689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl17$11,994
Xtampza ErOxycodone Myristate22$8,943
Buprenorphine29$7,933
Gabapentin104$1,517
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen104$915
Lidocaine14$837
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen56$724
Morphine Sulfate ErMorphine Sulfate23$500
Pregabalin39$385
Diclofenac Sodium14$239
Methylprednisolone32$209
Duloxetine Hcl11$202
Amitriptyline Hcl28$190
Acetaminophen-CodeineAcetaminophen With Codeine11$179
Topiramate28$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$301$20,93639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 interventional pain medicine providers in Michigan.

Other interventional pain medicine in Allen Park

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →